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Abstract
Low medication adherence may explain part of the high prevalence of apparent treatment resistant
hypertension (aTRH). We assessed medication adherence and aTRH among 4,026 participants
taking ≥ 3 classes of antihypertensive medication in the population-based REGARDS Study using
the 4-item Morisky Medication Adherence Scale (MMAS). Low adherence was defined as a
MMAS score ≥ 2. Overall, 66% of participants taking ≥ 3 classes of antihypertensive medication
had aTRH. Perfect adherence on the MMAS was reported by 67.8% and 70.9% of participants
with and without aTRH, respectively. Low adherence was present among 8.1% of participants
with aTRH and 5.0% of those without aTRH (p<0.001). Among those with aTRH, female gender,
residence outside the US stroke belt or stroke buckle, physical inactivity, elevated depressive
symptoms, and a history of coronary heart disease were associated with low adherence. In the
current study, a small percentage of participants with aTRH had low adherence.
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Introduction
Apparent treatment resistant hypertension (aTRH) is defined by the use of three classes of
antihypertensive medication with uncontrolled hypertension or the use of four or more
classes regardless of blood pressure (BP) control. 1 Using data from the National Health and
Nutrition Examination Survey (NHANES) 2005–2008, Egan and colleagues estimated
11.8% of all hypertensive US adults have aTRH. 2 This represents an almost 100% increase
since 1988–1994 when the prevalence of aTRH among US adults with hypertension was
5.5%. The diagnosis of TRH is complex and requires the exclusion of secondary causes of
uncontrolled hypertension. 1
Many individuals with aTRH may not undergo a comprehensive assessment of the potential
causes of their condition. Of particular relevance is low adherence to antihypertensive
medication. Low medication adherence is common among persons with hypertension and
many studies have reported low adherence to antihypertensive treatment to be associated
with worse BP control. 3–8 However, few data are available on antihypertensive medication
adherence among individuals with aTRH. Documenting the prevalence of low adherence in
aTRH may help better explain the high prevalence of this condition. Additionally,
identifying factors associated with low medication adherence can help target future
interventions to improve adherence in persons with aTRH. Therefore, we examined levels of
medication adherence compared to individuals taking three antihypertensive medication
classes who had controlled BP levels. Additionally, factors associated with low medication
adherence among individuals with aTRH were identified. For this investigation, we analyzed
data from a large, sample of US adults enrolled in the REasons for Geographic And Racial
Differences in Stroke (REGARDS) study. 9
Methods
Study Population
The REGARDS study has been described previously. 9 Briefly, the REGARDS study
included adults ≥ 45 years of age from all 48 continental US states and the District of
Columbia. Between January 2003 and October 2007, 30,239 individuals were enrolled into
the REGARDS study. By design, blacks and residents of the stroke belt and stroke buckle
region of the US were oversampled. The “stroke buckle” was defined by coastal North
Carolina, South Carolina, and Georgia and the “stroke belt” as the remainder of North
Carolina, South Carolina, and Georgia as well as Alabama, Mississippi, Tennessee,
Arkansas and Louisiana. The current study population was restricted to individuals treated
with three or more classes of antihypertensive medication (n=4,128) in order to make
comparisons for those with aTRH to a group treated with a comparable number of
antihypertensive medications. Participants missing BP data (n=17) or information on
medication adherence (n=85) were excluded leaving 4,026 participants for the analysis. The
REGARDS study protocol was approved by the Institutional Review Boards governing
research in human subjects at the participating centers and all participants provided
informed consent.
Data Collection
The current analysis used data from the baseline visit of the REGARDS study. Baseline
REGARDS study data were collected via a telephone interview, a self-administered
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questionnaire, and in-home examination. Of relevance to the current analysis, computer-
assisted telephone interviews administered by trained staff were used to collect information
on participants’ age, smoking status, education, physical activity, alcohol consumption,
symptoms of depression and self-reports of prior physician diagnosed co-morbid conditions
(e.g., diabetes, hypertension, stroke, and myocardial infarction). Elevated symptoms of
depression were defined as being present for participants with scores ≥ 4 on the 4-item
Centers for Epidemiologic Studies of Depression scale.10 Trained health professionals
conducted in-home examinations which included weight, height, BP measurements, an
electrocardiogram (ECG), the collection of blood and a spot urine sample, plus a review of
prescription and over the counter medications used over the prior 2 week period. Medication
names were recorded and subsequently coded into drug classes. Body mass index (BMI)
was calculated as weight in kilograms divided by height in meters squared. Coronary heart
disease (CHD) was defined by a self-reported history or ECG evidence of myocardial
infarction or a self-reported history of a revascularization procedure. Diabetes was defined
as a serum glucose ≥126 mg/dL for participants who had fasted ≥ 8 hours prior to their
blood draw, serum glucose ≥200 mg/dL for those who had not fasted, or self-report of a
prior diagnosis of diabetes while not pregnant with current use of insulin or oral
hypoglycemic medications. Using isotope-dilution mass spectrometry (IDMS)–traceable
serum creatinine, estimated glomerular filtration rate (eGFR) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 11 Low eGFR
was defined as levels < 60 ml/min/1.73 m2. Albuminuria was defined as being present for
individuals with a urinary albumin to urinary creatinine ratio ≥ 30 mg/g. Chronic kidney
disease was defined by the presence of low eGFR or albuminuria.
Blood pressure measurement, medication use and aTRH
During the in-home examination, BP was measured two times using aneroid
sphygmomanometers following a standardized protocol by trained examiners. Participants
were asked to sit for three minutes with both feet on the floor prior to the BP measurement.
Based on the average of the two measurements, uncontrolled hypertension was defined as a
systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg
except for individuals with diabetes or chronic kidney disease wherein uncontrolled
hypertension was defined as SBP ≥ 130 mmHg or DBP ≥ 80 mmHg, respectively.
Antihypertensive medication classes were defined using those listed in the Seventh Report
of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7). 12 They included ACE-inhibitors, aldosterone receptor
blockers, alpha blockers, angiotensin receptor blockers, beta blockers, calcium channel
blockers, central acting agents, diuretics, and direct vasodilators. One pill-combinations
were classified into individual medication classes. Information on medication dose was not
recorded. aTRH was defined as being present for participants taking three antihypertensive
medication classes with uncontrolled hypertension or taking four or more classes regardless
of hypertension control status.
Adherence
During the telephone interview, medication adherence was assessed using the 4-item
Morisky Medication Adherence Scale (MMAS). 13 The 4 items on the MMAS are (1) Do
you ever forget to take medications? (2) Are you ever careless in taking your medications?
(3) Do you ever miss taking your medications when you are feeling better? (4) Do you ever
miss taking any of your medications because you are feeling sick? Each item has a yes/no
response option. One point is assigned to each “yes” response, and points were summed
(totaling 0–4) with a higher score indicating worse adherence. 14 MMAS scores of 3 and 4
were pooled together for the current analysis due to a low number of participants in these
groups. Additionally, consistent with a previous analysis of REGARDS study data, 15
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individuals with MMAS scores of ≥ 2 were categorized as having low medication
adherence. In a prior study, the MMAS was reported to have acceptable internal consistency
(Cronbach’s a=0.61) and the items maintained a high item-to-total correlation (>0.4 for each
item). 13 Additionally, scores on the MMAS have been correlated with BP control
previously. 13
Statistical Analysis
The prevalence of aTRH was calculated for all REGARDS participants with hypertension
and for those with hypertension taking three or more antihypertensive medication classes.
Characteristics of REGARDS study participants taking three or more antihypertensive
medication classes were calculated by aTRH status with the statistical significance of
differences for those with controlled BP on three classes of antihypertensive medication
versus aTRH determined using chi square and t-tests, as appropriate. The percent of
participants with controlled BP (SBP/DBP < 140/90 mmHg except for individuals with
diabetes or chronic kidney disease wherein < 130/80 mmHg was required) was calculated by
MMAS scores. Responses to each MMAS item and the distribution of MMAS scores were
calculated by aTRH status and compared using chi-square tests. Next, for individuals with
aTRH, the odds ratios for low medication adherence associated with participant
characteristics were calculated using logistic regression. These characteristics included age,
race, gender, geographic region of residence, education, income, marital status, smoking
status, alcohol consumption, physical activity level, BMI, diabetes, reduced eGFR,
albuminuria, history of CHD or stroke, and elevated depressive symptoms. These variables
were chosen based on their observed association with low medication adherence in the
general population of persons with hypertension. 16 An initial model included adjustment for
age, race, gender, and geographic region of residence. A subsequent model included all
variables simultaneously. Data analysis was conducted using SAS version 9.2 (SAS
Institute, Cary, NC).
Results
Prevalence of apparent treatment resistant hypertension (aTRH)
In the REGARDS study, 16,927 participants had hypertension. For the current analysis, we
focused on the 4,026 (24% of those with hypertension) who were treated with three or more
antihypertensive medication classes. Overall, 2,654 REGARDS participants had aTRH. This
represents 16% of all REGARDS participants with hypertension and 66% of REGARDS
participants taking three or more antihypertensive classes. Of those with aTRH, 58% were
taking three classes of antihypertensive medication and had uncontrolled hypertension
(n=1,547) and 42% were taking four or more classes of antihypertensive medication
(n=1,107).
Participant characteristics
In comparison to those with controlled BP on three classes of antihypertensive medications,
those with aTRH were more likely to be black, men, have less than a high school education,
an annual household income less than $20,000, participate in less physical activity, and have
elevated depressive symptoms (Table 1). Each comorbidity (low eGFR, albuminuria,
diabetes and a history of CHD and stroke) was more common among individuals with
aTRH. Also, mean BMI was higher for individuals with versus without aTRH.
Level of medication adherence
The distribution of MMAS scores of 0 (best adherence) and 1, 2, and 3 or 4 (worst
adherence), was 68.8%, 24.1%, 5.0%, and 2.0%, respectively among the entire study
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population (N=4026). Individuals with worse adherence were less likely to have controlled
hypertension (Figure 1). The prevalence of controlled hypertension was 46.8%, 46.6%,
37.9%, and 27.2% for MMAS scores of 0, 1, 2, and 3 or 4, respectively.
While 28.9% of individuals with aTRH reported sometimes forgetting to take their
medication, this was reported by 26.4% of individuals taking three BP medications with
controlled hypertension (Table 2, p=0.088). Compared to participants with controlled BP on
three medications, those with aTRH were more likely to report being careless about taking
their medication and to stop taking their medication when they were feeling better or when
they were feeling worse. However, none of these three poor medication taking behaviors
was reported by more than 6% of individuals with aTRH. Overall MMAS scores were
significantly higher, indicating worse adherence, for individuals with aTRH (Figure 2).
Overall, 8.1% of individuals with aTRH and 5.0% of individuals with controlled BP while
taking three antihypertensive medications had low adherence defined by MMAS score ≥ 2
(p<0.001).
Factors associated with low medication adherence in aTRH
After adjustment for age, gender, and geographic region of residence, blacks were more
likely to have low medication adherence (Table 3, Model 1). After age, race, and geographic
region of residence adjustment, women were more likely than men to have low medication
adherence. After age, race, gender and geographic region of residence adjustment,
individuals with an annual household income < $20,000, elevated depressive symptoms and
a history of CHD were more likely to have low medication adherence. Additionally,
participants residing in the stroke belt or stroke buckle versus non-belt regions and those
participating in physical activity 1 to 3 or > 3 times per week were less likely to have low
medication adherence. The results were similar after full multivariable adjustment (Table 3,
Model 2) with the exception that the associations of black race and an annual household
income < $20,000 with low medication adherence were attenuated and no longer statistically
significant.
Discussion
Studies have consistently demonstrated low antihypertensive medication adherence is a
barrier for achieving adequate BP control. 8, 16 Therefore, low medication adherence may be
a major cause of aTRH among individuals taking multiple antihypertensive medications.
Low adherence to antihypertensive medications should be evaluated and excluded as a cause
of uncontrolled BP before a diagnosis of true TRH is made. 1 In the current study we
examined the association between low medication adherence and aTRH in individuals
taking antihypertensive medications from three or more classes using a validated scale in a
large population-based sample of US adults. While medication adherence was statistically
significantly better among individuals without versus with aTRH, the differences were
small. Almost 70% of individuals with and without aTRH reported good medication taking
behaviors according to all 4 adherence items in the 4 item MMAS. Furthermore, less than
10% of REGARDS participants with aTRH had low medication adherence, defined by
scores ≥ 2 on the 4-item MMAS. Our findings suggest that overall self-reported low
medication adherence in aTRH is quite low.
The prevalence of aTRH in the US has only recently been reported and is estimated to be
11–15% among persons with hypertension 2, 17, 18. The estimate we report in the
REGARDS cohort is slightly higher (16%) which may be due to over sampling of black
participants in the REGARDS study compared with other studies. For example,
approximately 15% of the NHANES 2005–2008 sample was black and that group was 2
times more likely to have aTRH 2. More recently using patient data collected over a 4-year
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period in the Kaiser Permanente Colorado and Northern California healthcare systems,
Daugherty and colleagues identified 205,750 patients who were started on antihypertensive
therapy for newly diagnosed hypertension 19. During follow-up, close to 21% were
eventually prescribed three or more medications and 24,499 participants were found eligible
for determination of aTRH status. Among that group the prevalence of aTRH was 16%. In
the current study the prevalence of aTRH among persons treated with three or more
antihypertensive medications was 66%. Differences between the current study and that of
Daugherty may be explained by the sampling of incident hypertension cases, low percentage
of blacks, and the relatively younger age of the cohort (on average 7 years younger) reported
on by Daugherty and colleagues. Among the 24,499 participants found eligible for
determination of aTRH status in the Daugherty study, only 587 (2.3%) were excluded from
further analysis for low medication adherence based on proportion of days covered <80%
determined by pharmacy fill rates. Like in the current study, the Daugherty study found a
small percentage of persons treated with 3 or more antihypertensive medications had low
adherence.
Small studies have previously examined the prevalence of non-adherence to
antihypertensive medication in the context of aTRH. One prospective study from Brazil in
44 persons with hypertension resistant to a three-drug regimen assessed adherence using the
4 item MMAS and pill count method. Overall, 36% of participants reported perfect
adherence at study initiation and this figure rose to 68% at one year. By pill count, 64% of
the population was adherent at the start of the study and 94% at the end, yet 60% of
participants did not achieve BP control. 20 In contrast, another study evaluated serum drug
levels in persons with difficult to treat hypertension (N=84) and found only 35% of study
participants to be perfectly adherent. 21 Whether low medication adherence is more
prevalent in aTRH than in a comparison group with a similar treatment regimen is less
studied. While significant differences in low medication adherence were present between the
REGARDS study participants with and without aTRH in the current analyses, these
differences were small. These results suggest factors other than low medication adherence
may contribute to hard-to-control BP in most persons with aTRH.
Despite the low rate of poor adherence in the current study, it is still important to evaluate
adherence among all persons with hypertension given the established association of
medication adherence with BP control. The strengths and weaknesses of various approaches
to assess medication adherence have been published previously. 22 The consequences of
uncontrolled BP are serious due to increased risk for poor clinical outcomes and increased
health care costs. 23–25 Few large population-based studies have examined the relationship
between adherence and BP control in individuals taking multiple antihypertensive
medications. In the current large population-based sample of US adults taking three or more
antihypertensive medication classes, we show a graded relationship between better
adherence and higher rates of BP control. The evaluation of low medication adherence in the
context of aTRH is especially important as some persons may not need to undergo
comprehensive clinical tests required for the diagnosis of true TRH. 1
While low medication adherence remains an important consideration when determining the
causes of aTRH, other factors including genes, environment, and their interactions may be
worthy of exploration in future studies. Recent reviews targeting strategies to uncover the
genetic background of complex traits (such as hypertension) have suggested extreme
phenotype samples (such as TRH) may be enriched for variants underlying the disease. 26, 27
Several small candidate gene studies have reported associations with TRH that warrant
follow-up investigations. 28–30 For instance, one study reported the angiotensinogen (AGT)
M235T polymorphism was associated with increased risk for TRH, especially after age 50,
highlighting a potential gene variant by age interaction. 29 Replication of preliminary results
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from smaller studies should be carried out in larger cohorts. Such studies will continue to
shed light on the mechanisms underlying TRH and could translate to better understanding of
the genetic background of less extreme forms of hypertension.
Many studies have considered factors affecting medication adherence in the general
population of hypertensives. 16, 31–35 However, factors affecting medication adherence in
aTRH have not been widely studied. In the current study of individuals with aTRH, women
were more likely to have low medication adherence. Previous studies in the general
population of individuals with hypertension have reported either no association of gender
with adherence or that women newly diagnosed with hypertension were more adherent than
men. 33, 36, 37 Consistent with reports in other chronic conditions and in
hypertension, 34, 38–42 elevated depressive symptoms were associated with low medication
adherence. We also found any physical activity to be protective against low medication
adherence. This may reflect a healthier lifestyle among people who are adherent.
Interestingly, our results suggest a history of CHD was associated with low medication
adherence. Low adherence to antihypertensive and lipid lowering medication has been
reported after myocardial infarction in prior studies. 43 Whether very complex treatment
regimens and/or persistence of behaviors associated with low medication adherence underlie
this association in aTRH requires further study.
There are several strengths and limitations regarding the current analysis which should be
mentioned. The adherence scale used in the REGARDS study was not specific to
antihypertensive medications and adherence was assessed only at a single time point.
Additionally, adherence was assessed using self-report only. Electronic data on medication
adherence (e.g., pharmacy fill data) is not available in the REGARDS study. While the 4-
item MMAS has been validated, participants may have provided socially desirable
responses. Additionally, we were unable to confirm optimal dosing of antihypertensive
medications as a criterion to define aTRH as dose was not recorded in the REGARDS study.
Despite these limitations, this study is the largest to characterize medication adherence in
aTRH and is strengthened by the population-based sample in REGARDS and use of an
adherence tool validated for studies of blood pressure control. Additionally, the large sample
size of the REGARDS study allowed for comparison of aTRH with people who had
controlled hypertension while on three antihypertensive medication classes. Finally, the
REGARDS study recruited individuals irrespective of socioeconomic or health insurance
status and used standardized protocols with stringent quality control procedures to collect
data.
In this population-based sample of black and white adults with hypertension treated with at
least three antihypertensive medication classes, better adherence was associated with higher
BP control rates. Among individuals with aTRH, 67.8% reported perfect adherence and only
8.1% had low medication adherence and this was comparable to participants on three
antihypertensive medication classes with controlled BP. Further, many factors previously
reported to be associated with low medication adherence in persons with hypertension were
also associated with low medication adherence when investigated among individuals with
aTRH. Taken together these results help to distinguish TRH as an extreme phenotype within
uncontrolled hypertension and emphasize the need for further studies to help better define its
etiology. In the meantime, health care providers should continue to assess adherence and
assist patients with aTRH in overcoming barriers to taking their medication, similarly to
other patients with hypertension.
Irvin et al. Page 7














This research project is supported by a cooperative agreement U01 NS041588 from the National Institute of
Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service. The
content is solely the responsibility of the authors and does not necessarily represent the official views of the
National Institute of Neurological Disorders and Stroke or the National Institutes of Health. Representatives of the
funding agency have been involved in the review of the manuscript but not directly involved in the collection,
management, analysis or interpretation of the data. The authors thank the other investigators, the staff, and the
participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS
investigators and institutions can be found at http://www.regardsstudy.org
References
1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment:
a scientific statement from the American Heart Association Professional Education Committee of
the Council for High Blood Pressure Research. Circulation. Jun; 2008 117(25):e510–526. [PubMed:
18574054]
2. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment
resistant hypertension in the United States, 1988 to 2008. Circulation. Aug; 2011 124(9):1046–
1058. [PubMed: 21824920]
3. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with
antihypertensive therapy. J Clin Hypertens (Greenwich). Jul; 2009 11(7):376–382. [PubMed:
19583634]
4. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive
medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in
primary care. J Hypertens. Nov; 2005 23(11):2093–2100. [PubMed: 16208153]
5. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence
with antihypertensive drugs. J Hypertens. Nov; 2005 23(11):2101–2107. [PubMed: 16208154]
6. Yiannakopoulou, ECh; Papadopulos, JS.; Cokkinos, DV.; Mountokalakis, TD. Adherence to
antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev
Rehabil. Jun; 2005 12(3):243–249. [PubMed: 15942423]
7. Romanelli RJ, Schiro TA, Jukes T, Wong KS, Ishisaka DY. Disparities in blood pressure control
within a community-based provider network: an exploratory analysis. Ann Pharmacother. Dec;
2011 45(12):1473–1482. [PubMed: 22147145]
8. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review
of 50 years of research. Med Care. Mar; 2004 42(3):200–209. [PubMed: 15076819]
9. Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke
study: objectives and design. Neuroepidemiology. 2005; 25(3):135–143. [PubMed: 15990444]
10. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population.
Applied Psychological Measurement. 1977:385–401.
11. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate.
Ann Intern Med. May; 2009 150(9):604–612. [PubMed: 19414839]
12. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. Dec;
2003 42(6):1206–1252. [PubMed: 14656957]
13. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure
of medication adherence. Med Care. Jan; 1986 24(1):67–74. [PubMed: 3945130]
14. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying
nonadherence with cardiovascular medications. Ann Pharmacother. Sep; 2004 38(9):1363–1368.
[PubMed: 15238622]
15. Muntner P, Halanych JH, Reynolds K, et al. Low medication adherence and the incidence of stroke
symptoms among individuals with hypertension: the REGARDS study. J Clin Hypertens
(Greenwich). Jul; 2011 13(7):479–486. [PubMed: 21762360]
Irvin et al. Page 8













16. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in
achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin
Cardiol. Jul; 2004 19(4):357–362. [PubMed: 15218396]
17. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension.
Jun; 2011 57(6):1076–1080. [PubMed: 21502568]
18. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation.
Apr; 2012 125(13):1594–1596. [PubMed: 22379111]
19. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in
hypertensive patients. Circulation. Apr; 2012 125(13):1635–1642. [PubMed: 22379110]
20. de Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar-Toledo JC, Moreno H.
Intensive monitoring of adherence to treatment helps to identify “true” resistant hypertension. J
Clin Hypertens (Greenwich). Apr; 2009 11(4):183–191. [PubMed: 19614802]
21. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial
hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to
differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res.
Jan; 2011 34(1):87–90. [PubMed: 20882030]
22. Krousel-Wood M, Hyre A, Muntner P, Morisky D. Methods to improve medication adherence in
patients with hypertension: current status and future directions. Curr Opin Cardiol. Jul; 2005
20(4):296–300. [PubMed: 15956826]
23. Esposti LD, Saragoni S, Benemei S, et al. Adherence to antihypertensive medications and health
outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res. 2011; 3:47–54.
[PubMed: 21935332]
24. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on
hospitalization risk and healthcare cost. Med Care. Jun; 2005 43(6):521–530. [PubMed:
15908846]
25. Stroupe KT, Teal EY, Tu W, Weiner M, Murray MD. Association of refill adherence and health
care use among adults with hypertension in an urban health care system. Pharmacotherapy. Jun;
2006 26(6):779–789. [PubMed: 16716131]
26. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases.
Nature. Oct; 2009 461(7265):747–753. [PubMed: 19812666]
27. Shi G, Rao DC. Optimum designs for next-generation sequencing to discover rare variants for
common complex disease. Genet Epidemiol. Sep; 2011 35(6):572–579. [PubMed: 21618604]
28. Hannila-Handelberg T, Kontula K, Tikkanen I, et al. Common variants of the beta and gamma
subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels
in essential hypertension. BMC Med Genet. Jan.2005 6:4. [PubMed: 15661075]
29. Yugar-Toledo JC, Martin JF, Krieger JE, et al. Gene variation in resistant hypertension: multilocus
analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide
synthase genes. DNA Cell Biol. Aug; 2011 30(8):555–564. [PubMed: 21438754]
30. Cruz-Gonzalez I, Corral E, Sanchez-Ledesma M, Sanchez-Rodriguez A, Martin-Luengo C,
Gonzalez-Sarmiento R. An association between resistant hypertension and the null GSTM1
genotype. J Hum Hypertens. Aug; 2009 23(8):556–558. [PubMed: 19279659]
31. World Health Organization. Hypertension in Adherence to Long-Term Therapies: Evidence for
Action. 2003.
32. Furberg CD, Black DM. The systolic hypertension in the elderly pilot program: methodological
issues. Eur Heart J. Feb; 1988 9(2):223–227. [PubMed: 3350031]
33. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class.
Can J Cardiol. Jun; 2002 18(6):649–656. [PubMed: 12107422]
34. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with
antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen
Intern Med. Jul; 2002 17(7):504–511. [PubMed: 12133140]
35. Kim MT, Han HR, Hill MN, Rose L, Roary M. Depression, substance use, adherence behaviors,
and blood pressure in urban hypertensive black men. Ann Behav Med. Aug; 2003 26(1):24–31.
[PubMed: 12867351]
Irvin et al. Page 9













36. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for
hypertension in actual practice. CMAJ. Jan; 1999 160(1):31–37. [PubMed: 9934341]
37. Krousel-Wood MA, Muntner P, Islam T, Morisky DE, Webber LS. Barriers to and determinants of
medication adherence in hypertension management: perspective of the cohort study of medication
adherence among older adults. Med Clin North Am. May; 2009 93(3):753–769. [PubMed:
19427503]
38. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment
nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. Oct; 2011 58(2):181–
187. [PubMed: 21857529]
39. Morris AB, Li J, Kroenke K, Bruner-England TE, Young JM, Murray MD. Factors associated with
drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. Apr;
2006 26(4):483–492. [PubMed: 16553506]
40. Maguire LK, Hughes CM, McElnay JC. Exploring the impact of depressive symptoms and
medication beliefs on medication adherence in hypertension--a primary care study. Patient Educ
Couns. Nov; 2008 73(2):371–376. [PubMed: 18692978]
41. Wang PS, Avorn J, Brookhart MA, et al. Effects of noncardiovascular comorbidities on
antihypertensive use in elderly hypertensives. Hypertension. Aug; 2005 46(2):273–279. [PubMed:
15983239]
42. Krousel-Wood M, Islam T, Muntner P, et al. Association of depression with antihypertensive
medication adherence in older adults: cross-sectional and longitudinal findings from CoSMO. Ann
Behav Med. Dec; 2010 40(3):248–257. [PubMed: 20703839]
43. Akincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to evidence
based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med. Feb;
2008 23(2):115–121. [PubMed: 17922172]
Irvin et al. Page 10














Hypertension control rates associated with level of medication adherence among REGARDS
participants taking at least three antihypertensive medication classes.
Irvin et al. Page 11














Level of adherence among REGARDS study participants by apparent treatment resistant
hypertension status.
Irvin et al. Page 12

























Irvin et al. Page 13
Table 1
Characteristics of REGARDS study participants taking three or more antihypertensive medication classes by
apparent treatment resistant hypertension status.
Controlled on 3 medicationsa (n=1,372) Apparent treatment resistant hypertensionb
(n=2,654)
p-value
Age, years 67.3 (8.8) 67.4 (8.7) 0.69
Black, % 46.9% 60.0% <0.001
Male, % 40.7% 48.2% <0.001
Region of residence
 Non-belt 42.1% 45.3% 0.08
 Stroke belt 35.1% 34.6%
 Stroke buckle 22.8% 20.2%
< HS education 14.1% 19.9% <0.001
Household Income < $20K per year 23.6% 28.5% 0.002
Currently married 55.0% 53.7% 0.41
Current smoking 11.4% 12.5% 0.33
Physical activity
 None 40.4% 44.4% 0.007
 1 to 3 times per week 32.7% 32.9%
 > 3 times per week 26.9% 22.7%
Alcohol consumption
 None 68.1% 70.0% 0.30
 Moderate 28.3% 27.1%
 Heavy 3.6% 2.9%
BMI, kg/m2 30.8 (6.2) 32.4 (6.8) <0.001
Depressive symptoms, % c 11.5% 14.4% 0.01
Low eGFR < 60 ml/min/1.73 m2 22.9% 33.6% <0.001
Albuminuria, % 12.8% 35.7% <0.001
Diabetes, % 27.3% 49.6% <0.001
History of CHD, % 29.2% 34.6% <0.001
History of stroke, % 11.2% 13.4% 0.05
Abbreviations: BP – blood pressure, HS – high school, BMI – body mass index, eGFR – estimated glomerular filtration rate, CHD – coronary heart
disease
aControlled blood pressure was defined as systolic/diastolic blood pressure < 140/90 mmHg except for individuals with diabetes or chronic kidney
disease wherein controlled blood pressure was systolic/diastolic blood pressure <130/80 mmHg.
b
Treatment resistant hypertension was defined as having uncontrolled blood pressure while on 3 antihypertensive medication classes or taking 4
antihypertensive medication classes regardless of blood pressure control.
cScore ≥ 4 on the 4-item Centers for Epidemiologic Studies of Depression scale.
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Table 2
Responses to individual 4-item Morisky Medication Adherence Scale (MMAS) questions by apparent
treatment resistant hypertension status.





1. Sometimes forget to take medication (Yes) 26.4% 28.9% 0.09
2. Careless about taking medication (Yes) 2.6% 4.6% 0.003
3. Stop taking medication when feeling better (Yes) 3.5% 5.9% <0.001
4. Stop taking medication when feeling worse (Yes) 3.0% 4.3% 0.04
aControlled blood pressure was defined as systolic/diastolic blood pressure < 140/90 mmHg except for individuals with diabetes or chronic kidney
disease wherein controlled blood pressure was systolic/diastolic blood pressure <130/80 mmHg.
b
Treatment resistant hypertension was defined as having uncontrolled blood pressure while on 3 antihypertensive medication classes or taking 4
antihypertensive medication classes regardless of blood pressure control.
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Table 3
Odds ratios for low medication adherence defined as 4-item Morisky Medication Adherence Scale (MMAS)
score ≥2 among REGARDS study participants with apparent treatment resistant hypertension.
Odds ratio (95% CI) for low adherence
Model 1a Model 2b
Age, per 10 years 0.88 (0.75 – 1.04) 0.83 (0.68 – 1.01)
Black 1.47 (1.07 – 2.02) 1.33 (0.93 – 1.91)
Male 0.70 (0.53 – 0.94) 0.64 (0.44 – 0.93)
Residence in stroke belt 0.69 (0.50 – 0.95) 0.66 (0.46 – 0.95)
Residence in stroke buckle 0.50 (0.33 – 0.76) 0.49 (0.31 – 0.78)
< HS education 1.30 (0.93 – 1.84) 1.09 (0.73 – 1.63)
Household Income < $20K per year 1.56 (1.12 – 2.16) 1.32 (0.88 – 1.97)
Currently married 0.99 (0.72 – 1.36) 1.22 (0.84 – 1.97)
Current smoking 1.36 (0.92 – 2.00) 1.18 (0.75 – 1.85)
Body mass index, kg/m2
 < 25 1 (ref) 1 (ref)
 25 to 29 0.70 (0.44 – 1.10) 0.71 (0.42 – 1.19)
 ≥ 30 0.73 (0.48 – 1.10) 0.75 (0.47 – 1.21)
Physical activity
 None 1 (ref) 1 (ref)
 1 to 3 times per week 0.58 (0.42 – 0.81) 0.60 (0.42 – 0.87)
 > 3 times per week 0.61 (0.41 – 0.89) 0.66 (0.43 – 1.00)
Alcohol consumption
 None 1 (ref) 1 (ref)
 Moderate 0.94 (0.67 – 1.33) 0.98 (0.67 – 1.43)
 Heavy 0.92 (0.36 – 2.34) 0.86 (0.29 – 2.50)
Depressive symptoms 1.74 (1.23 – 2.46) 1.62 (1.09 – 2.40)
Low eGFR < 60 ml/min/1.73 m2 0.93 (0.68 – 1.26) 0.83 (0.58 – 1.18)
Albuminuria 1.08 (0.79 – 1.47) 1.06 (0.76 – 1.48)
Diabetes 0.88 (0.66 – 1.18) 0.87 (0.63 – 1.20)
History of CHD 1.61 (1.20 – 2.16) 1.54 (1.11 – 2.15)
History of stroke 1.07 (0.72 – 1.61) 0.75 (0.47 – 1.20)
a
Model 1 included age, race, gender, and geographic region of residence.
b
Model 2 included all variables simultaneously.
cScore ≥ 4 on the 4-item Centers for Epidemiologic Studies of Depression scale.
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